Despite a significant progress in early diagnosis and treatment, resistance to conventional chemotherapeutics continuously poses a tremendous challenge to effective triple breast cancer therapy. The present project proposes the development of novel nanocarrier systems to deliver miR34a and different drugs ((D) = Docetaxel (DCT), Doxorubicin (DOX), Paclitaxel (PXL) and Nintedanib (NTB)) in human triple negative breast cancer cells (MDAMB231) to inhibit both, their growth and migration. For this aim, novel non viral nanopolyplex vectors containing oligosaccharide fragments of hyaluronic acid (oHA) with high affinity for the surface receptor CD44 overexpressed in human triple negative breast cancer cells (MDAMB231) will be designed. It will be the first time that oHA will be used to the creation of non viral gene delivery systems. It is expected that this strategy could improve the encapusalting capacity of the nanopolyplexes and their in vitro and in vivo antitumor activity. This proposed research will cover a vast range of interdisciplinary research, starting from the design and synthesis of novel nanopolyplexes systems, structural and physical characterization of the synthesized materials, encapsulation of gene and drugs and study of their properties for gene and drug delivery in a triple breast cancer model.